Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088721 | 0.93 | KCNH2 (0.48) | MAPTSMN1; SMN2KCNH2RXFP1MAPK8 | |
| SCHEMBL4089993 | 0.92 | KMT2A (0.48) | MAPTSMN1; SMN2KCNH2RXFP1LMNA | |
| SCHEMBL4094097 | 0.91 | LMNA (0.50) | MAPTSMN1; SMN2LMNAALDH1A1ALOX12 | |
| SCHEMBL3001524 | 0.90 | PLA2G2A (0.46) | MAPTKCNH2LMNAALDH1A1 | |
| SCHEMBL4098796 | 0.90 | KMT2A (0.46) | MAPTSMN1; SMN2KCNH2LMNAALDH1A1 | |
| SCHEMBL3001563 | 0.89 | ALDH1A1 (0.50) | MAPTSMN1; SMN2LMNAALDH1A1ALOX12 | |
| SCHEMBL4097877 | 0.89 | FAAH (0.51) | MAPTSMN1; SMN2KCNH2RXFP1 | |
| SCHEMBL4096113 | 0.89 | KCNH2 (0.48) | MAPTSMN1; SMN2KCNH2RXFP1ALDH1A1 | |
| SCHEMBL3006333 | 0.89 | MAPT (0.43) | MAPTSMN1; SMN2KCNH2RXFP1LMNA | |
| SCHEMBL4089939 | 0.88 | MEN1 (0.45) | MAPTSMN1; SMN2KCNH2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| EP-2049520-A2 | INDOLE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008019357-A2 | INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | MAPT 2737/4885SMN1; SMN2 4055/4885KCNH2 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.